Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 study of teduglutide in Chinese adults with short bowel syndrome dependent on parenteral support
CTR20251511Phase 3Active
- Sponsor
- Takeda
- Start
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of teduglutide in short bowel syndrome (SBS), sponsored by Takeda. Started Aug 2025; status: active.
02
Drugs
teduglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on CTR20251511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251511.